Intended for licensed healthcare professionals located in Norway.

Read the compulsory
Prescribing Information here Summary of Product Characteristics (SmPC) Report an adverse event
ESMO guideline recommendations FGFR2 fusion testing
About PEMAZYRE
Efficacy Safety
Dosing and administration Request a meeting Stay informed
Read the compulsory
Prescribing Information here Summary of Product Characteristics (SmPC) Report an adverse event

Cookie Policy

Privacy Policy Cookie Policy Terms of Use If you would like to request further medical information, please visit:
https://www.incyteglobalmedicalinformation.com/
Marketing authorisation holder:
Incyte Biosciences Distribution B.V.
Paasheuvelweg 25
1105 BP Amsterdam
Netherlands

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions to their local authority or to Incyte (by e-mail: eumedinfo@incyte.com).

NO/PEMA/P/23/0003
Date of Preparation: November 2023
© 2023, Incyte. All rights reserved.
PEMAZYRE, the PEMAZYRE logo and the Incyte logo are registered trademarks of Incyte.

Back to top

External link disclaimer

Intended for licensed healthcare professionals located in Norway only.

You are now leaving the Incyte PEMAZYRE website. This link will take you to a site that is not owned or maintained by Incyte. Incyte is not responsible for the information contained on third⁠–⁠party sites. Would you like to continue?

Yes No

Report an adverse event